Lenalidomide and R-CHOP in B-cell Lymphoma
The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone).
Lymphoma, Large B-Cell, Diffuse|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma
DRUG: Lenalidomide and R-CHOP
Incidence of Dose Limiting Toxicities, 42 days
Complete response rate and Overall response rate at the end of treatment, 3 months after the end of treatment|Complete and Overall response rates after induction, at the end of third cycle of treatment (between Day 56 and Day 63)|Progression-Free Survival and Overall survival, 7 years|Duration of response, 7 years|Collection of adverse events, 6 months
The study is a dose escalation study of lenalidomide (Revlimid) administered orally during 14 days in combination with fixed doses of rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks (R-CHOP 21) in patients with B-cell lymphoma.